Yan Li
Yan Li has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Chuanfei Yu
National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Daxing District, Beijing 102629, China; State Key Laboratory of Drug Regulatory Science, Beijing 102629, China
2 shared publications - Tao Tang
Sichuan Institute for Drug Control, Chengdu, China; NMPA Center for Innovation and Research in Regulatory Science, Chengdu, China, China
2 shared publications - Xiaojuan Yu
State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102629, China
2 shared publications - Yalan Yang
National Institutes for Food and Drug Control, Beijing, China; State Key Laboratory of Drug Regulatory Science, Beijing, China; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, China; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, China, China
2 shared publications - Yao Tang
NMPA Center for Innovation and Research in Regulatory Science, Sichuan Institute for Drug Control, SCMPA Key Laboratory for Quality Monitoring and Risk Assessment of Biological Products, Chengdu 611731, China
2 shared publications Congyan Shu
1 shared publication
Latest Publications
- Open Access
- 20 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1495
Critical Quality Attribute Investigation and Analytical Method Establishment for Glyco-Site-Specific Anti-HER2 Bispecific ADC
Background/Objectives: Bispecific antibody–drug conjugates (bispecific ADCs) are among the most rapidly advancing antibody therapeutic modalities, with only one product (BL-B01D1) currently approved for marketing worldwide to date. In this study, we investigated several critical quality attributes (CQAs) of a glyco-site-specific antibody–drug conjugate (ADC) targeting two distinct epitopes of HER2. Methods: We established quality control methods for the assessment of mispaired species, conjugation site, drug-to-antibody ratios (DARs), charge variants, residual free drugs, residual β1,4-galactosyltransferase I (GalT) enzyme, relative binding activity, and cell proliferation inhibition activity. Conclusions: An analytical method suite was developed for the bispecific ADC to comprehensively characterize and appropriately control its critical quality attributes, thereby guiding the research, development, and manufacturing process optimization of the ADC product and ensuring its safety, efficacy, and quality consistency.
- 20 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1495
Open AccessCritical Quality Attribute Investigation and Analytical Method Establishment for Glyco-Site-Specific Anti-HER2 Bispecific ADC
Background/Objectives: Bispecific antibody–drug conjugates (bispecific ADCs) are among the most rapidly advancing antibody therapeutic modalities, with only one product (BL-B01D1) currently approved for marketing worldwide to date. In this study, we investigated several critical quality attributes (CQAs) of a glyco-site-specific antibody–drug conjugate (ADC) targeting two distinct epitopes of HER2. Methods: We established quality control methods for the assessment of mispaired species, conjugation site, drug-to-antibody ratios (DARs), charge variants, residual free drugs, residual β1,4-galactosyltransferase I (GalT) enzyme, relative binding activity, and cell proliferation inhibition activity. Conclusions: An analytical method suite was developed for the bispecific ADC to comprehensively characterize and appropriately control its critical quality attributes, thereby guiding the research, development, and manufacturing process optimization of the ADC product and ensuring its safety, efficacy, and quality consistency.
- Open Access
- 29 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 860
Advancements in Dual-Load Antibody–Drug Conjugates and Challenges with Quality Analysis
Antibody–drug conjugates (ADCs) are a pivotal technology for precision cancer therapy, harnessing the synergistic effects of antibody targeting and toxin delivery. However, traditional ADCs encounter limitations in efficacy that stem from tumor resistance, heterogeneity, and intense target competition. Dual-payload ADCs (DP-ADCs) represent a promising solution to these challenges, as they leverage dual mechanisms of action that mitigate acquired drug resistance and enhance adaptability to tumor heterogeneity. The complex structure of DP-ADCs presents substantial quality control hurdles. In this manuscript, we review the current payload selection and conjugation strategies of DP-ADCs and examine recent advances in quality control research. Specifically, we analyze the analytical challenges related to the quantification of free toxins, the determination of the total antibody content, and the characterization of the drug-to-antibody ratio and its distribution. Ultimately, the aim of this work is to provide valuable guidance for future DP-ADC quality control analyses to facilitate their clinical translation and application.
- 29 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 860
Open AccessAdvancements in Dual-Load Antibody–Drug Conjugates and Challenges with Quality Analysis
Antibody–drug conjugates (ADCs) are a pivotal technology for precision cancer therapy, harnessing the synergistic effects of antibody targeting and toxin delivery. However, traditional ADCs encounter limitations in efficacy that stem from tumor resistance, heterogeneity, and intense target competition. Dual-payload ADCs (DP-ADCs) represent a promising solution to these challenges, as they leverage dual mechanisms of action that mitigate acquired drug resistance and enhance adaptability to tumor heterogeneity. The complex structure of DP-ADCs presents substantial quality control hurdles. In this manuscript, we review the current payload selection and conjugation strategies of DP-ADCs and examine recent advances in quality control research. Specifically, we analyze the analytical challenges related to the quantification of free toxins, the determination of the total antibody content, and the characterization of the drug-to-antibody ratio and its distribution. Ultimately, the aim of this work is to provide valuable guidance for future DP-ADC quality control analyses to facilitate their clinical translation and application.